Since Our Last Update
Since our last update, Dyadic International Inc. DYAI announced receipt of the NIIMBL coronavirus grant, early proof-of-concept of C1 producing cannabinoids and an exclusive license agreement with Phibro.
➢ NIIMBL coronavirus grant - December 2021
➢ C1 engineered to demonstrate the potential to produce cannabinoids - January 2022
➢ Phibro exclusive license agreement for animal health vaccine - February 2022
NIIMBL Coronavirus Grant
On December 22nd, 2021, Dyadic announced receipt of a National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) coronavirus grant under the White House's American Rescue Plan (ARP). Dyadic's grant was one of 32 project grants awarded by NIIMBL and through the grant, Dyadic will receive up to $690,000 in funding to support its development of C1 production of two different antibodies. The grant is intended to benchmark the rate of the C1 manufacturing platform against current state of the art methods, within the context of producing medical countermeasures and vaccines in response to future pandemics.
C1 Successfully Engineered to Produce Cannabinoids
On January 20, 2022, Dyadic revealed that it has engineered C1 to produce cannabis compounds including cannabidiol (CBD). C1 has the potential to synthesize pure cannabinoids for commercial use at less cost and more efficiently compared to sourcing directly from the Cannabis sativa plant. C1 cell factories should require less energy and be more environmentally friendly than commercial agriculture operations, especially in terms of harvesting and isolation of the desired cannabinoids from plant matter. Chemical synthesis of these compounds can utilize costly, environmentally concerning reactants. C1 could represent a high-quality and low-cost option to produce consumer product with applications in pain, multiple sclerosis, cancer-associated nausea and vomiting, weight loss, appetite loss and spasticity among others. The press release continued on to summarize a recent peer-reviewed publication which found that two cannabinoid acids CBGA and CBDA had micromolar binding affinity for the coronavirus spike protein, which could have prophylactic properties preventing infection. The compounds were also reported to be equally effective against two SARS-CoV-2 variants, and could be effective against future mutant strains.
Phibro Exclusive License Agreement
On February 10, 2022, Dyadic announced an exclusive license agreement with Phibro Animal Health PAHC to develop and commercialize an animal health vaccine for a Phibro targeted disease. Phibro is a leading global animal health and mineral nutrition company. The agreement was realized after previous proof of concept development work between the two companies. Under the terms of the agreement, Dyadic granted Phibro exclusive license to C1 to produce specific targeted antigens for a poultry vaccine in a disease of Phibro's choice. Development work to find and develop additional vaccine candidates using C1 will continue. Phibro offers more than 25 poultry vaccines including Infectious Bursal Disease, Infectious Bronchitis and Newcastle Disease. Poultry vaccines are estimated to be a ~$2 billion market.1
Since our last update, Dyadic has made several announcements regarding the NIIMBL coronavirus grant, early proof-of-concept of C1 producing cannabinoids, and an exclusive license agreement with Phibro. Dyadic will receive up to $690,000 to support the development of two different C1-expressed antibodies, and C1 will be benchmarked for its manufacturing rate. Dyadic also successfully engineered C1 to produce cannabinoids. Finally, Dyadic entered into an exclusive license agreement with Phibro for the development and commercialization of a poultry vaccine. There is substantial value in Dyadic's broad portfolio of options and in its exciting technology that can revolutionize the protein expression industry. Future favorable catalysts include the addition of more collaborators, achieving output milestones and launching the planned clinical trial.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.